Cogent Biosciences Inc (COGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -226,445 | -145,515 | -71,986 | -255,859 | -187,932 |
| Depreciation Amortization | 1,393 | 619 | -315 | -5,169 | -3,190 |
| Accounts payable and accrued liabilities | 4,016 | 4,612 | 2,141 | 1,358 | 4,406 |
| Other Working Capital | 7,879 | 3,119 | -4,716 | 11,596 | 12,727 |
| Other Operating Activity | 27,818 | 16,112 | 8,365 | 40,283 | 26,775 |
| Operating Cash Flow | $-185,339 | $-121,053 | $-66,511 | $-207,791 | $-147,214 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -743 | -678 | -547 | -573 | -498 |
| Purchase Of Investment | -291,949 | -67,883 | N/A | -255,603 | -242,879 |
| Sale Of Investment | 215,935 | 146,850 | 69,926 | 294,452 | 219,982 |
| Investing Cash Flow | $-76,757 | $78,289 | $69,379 | $38,276 | $-23,395 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 49,291 | 49,291 | N/A | N/A | N/A |
| Common Stock Issued | 242,577 | 24,975 | 24,970 | 214,451 | 214,425 |
| Other Financing Activity | -2,304 | -2,069 | 0 | 0 | 0 |
| Financing Cash Flow | $289,564 | $72,197 | $24,970 | $214,451 | $214,425 |
| Beginning Cash Position | 98,165 | 98,165 | 98,165 | 53,229 | 53,229 |
| End Cash Position | 125,633 | 127,598 | 126,003 | 98,165 | 97,045 |
| Net Cash Flow | $27,468 | $29,433 | $27,838 | $44,936 | $43,816 |
| Free Cash Flow | |||||
| Operating Cash Flow | -185,339 | -121,053 | -66,511 | -207,791 | -147,214 |
| Capital Expenditure | -743 | -678 | -547 | -573 | -498 |
| Free Cash Flow | -186,082 | -121,731 | -67,058 | -208,364 | -147,712 |